Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours

Paquet, M.; Gauthé, Mathieu; Zhang-Yin, Jules; Nataf, Valérie; Belissant, Ophélie; Orcel, Philippe; Roux, Christian; Talbot, Jean-Noël; Montravers, F.

doi:10.1007/s00259-018-3971-x

Cited by 31 publications

(46 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No additional records were found screening the references of these articles, whereas six articles were excluded after the analysis of the full text. Therefore, 14 articles were included in the qualitative analysis (systematic review) [16][17][18][19][20][21][22][23][24][25][26][27][28][29]. Three articles were excluded from the meta-analysis for possible patient data overlap [18,25,26].…”

Section: Literature Searchmentioning

confidence: 99%

“…Three articles were excluded from the meta-analysis for possible patient data overlap [18,25,26]. Overall, 11 articles (166 patients with TIO) were included in the quantitative analysis (meta-analysis) [16,17,[19][20][21][22][23][24][27][28][29]. The characteristics of the 14 studies included in the systematic review are presented in Tables 1 and 2.…”

Section: Literature Searchmentioning

confidence: 99%

“…As shown in Table 3, most of the selected studies showed a good DR of culprit tumors in patients with TIO using SSTR-PET/CT. The culprit lesions were usually small benign tumors located in the bones or soft tissues, presenting a high uptake of radiolabeled somatostatin analogues ( 68 Ga-DOTATATE, 68 Ga-DOTATOC or 68 Ga-DOTANOC) at SSTR-PET/CT [16][17][18][19][20][21][22][23][24][25][26][27][28][29]. The most frequent site of culprit tumors were the lower limbs; other frequent sites were the cranio-facial region and the trunk, whereas the localization of culprit tumors in the upper limbs was less frequent.…”

Section: Main Findingsmentioning

confidence: 99%

“…Malignant or metastatic tumors detected by SSTR-PET/CT in patients with TIO were rare [16][17][18][19][20][21][22][23][24][25][26][27][28][29]. A very high inter-observer concordance among PET/CT masked readers was reported by one study for the visual detection of culprit tumors by SSTR-PET/CT [20]. Interestingly, a significant correlation between SUVmax of the culprit tumor at SSTR-PET/CT and serum FGF23 levels was not reported [17,20].…”

Section: Main Findingsmentioning

confidence: 99%

See 3 more Smart Citations

Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

Background: Tumor-induced or oncogenic osteomalacia (TIO) is a rare paraneoplastic syndrome in which osteomalacia is a consequence of fibroblast growth factor 23 (FGF23) secretion by a mesenchymal tumor. The localization of the culprit lesion in patients with TIO is often challenging. Several studies have evaluated the detection rate (DR) of these tumors using somatostatin receptor positron emission tomography (SSTR-PET/CT). We aimed to summarize literature findings on this topic providing pooled estimates of DR. Methods: A comprehensive literature search by screening PubMed, Embase and Cochrane library electronic databases through August 2019 was performed. The pooled DR of culprit tumors using SSTR-PET/CT in patients with TIO was calculated using a random-effects statistical model. Results: Fourteen studies on the use of SSTR-PET/CT in detecting the culprit tumor in patients with TIO were included in the qualitative analysis. The pooled DR of SSTR-PET/CT on a per-patient-based analysis calculated using eleven studies (166 patients) was 87.6% (95% confidence interval (95% CI) 80.2–95.1%). Statistical heterogeneity among studies was detected (I-square = 63%), likely due to the use of different radiolabeled somatostatin analogues, as demonstrated by a subgroup analysis. Conclusions: Despite limited literature data due to the rarity of the disease, SSTR-PET/CT demonstrated a very high DR of culprit tumors in patients with TIO and it could be used as first-line imaging method for this indication.

show abstract

Section: Literature Searchmentioning

confidence: 99%

Section: Literature Searchmentioning

confidence: 99%

Section: Main Findingsmentioning

confidence: 99%

Section: Main Findingsmentioning

confidence: 99%

See 2 more Smart Citations

Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Another complex using a different somatostatin analog (Tyr3-octreotate, TATE), 68 Ga-DOTA-TATE has also been used in several tumor-type detection and is part of ongoing clinical trials for metastatic castration-resistant prostate cancer diagnostics [51,52]. Edotreotide (TOC), with a special affinity for type 2 somatostatin receptors has also been used combined with 68 Ga-DOTA ( 68 Ga-DOTA-TOC) to diagnose cancerous lesions [53][54][55]. Bombesin, which is a peptide found in the intrinsic nerves of the gastrointestinal tract, has also been used in conjunction with 68 Ga to diagnose tumor lesions targeting gastrin-releasing peptide receptors [56,57].…”

Section: Small Molecule Clinical Applications Of 68 Gamentioning

confidence: 99%

Molecular Imaging with 68Ga Radio-Nanomaterials: Shedding Light on Nanoparticles

et al. 2018

View full text Add to dashboard Cite

Abstract:The combination of radioisotopes and nanomaterials is creating a new library of tracers for molecular imaging, exploiting the sensitivity of nuclear imaging techniques and the size-dependent properties of nanomaterials. This new approach is expanding the range of applications, including the possibility of theranostics. Among the many different combinations, the use of 68 Ga as the radioisotope in the radio-nanomaterial is particularly convenient. The physicochemical properties of this isotope allow incorporating it into many materials with great chemical flexibility. Furthermore, its production from a benchtop generator eases the preparation of the tracer. Here, we review main results from the last years in which a nanomaterial has been radiolabeled with 68 Ga. In thus process, we pay attention to the use of nanomaterials for biomedical imaging in general and main properties of this radioisotope. We study the main methods to carry out such radiolabeling and the most important applications for molecular imaging.

show abstract

Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective Surveillance

Hidaka

Koga

Kimura

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Tumor-induced osteomalacia (TIO) is an acquired fibroblast growth factor 23 (FGF23)-related hypophosphatemic osteomalacia caused by phosphaturic mesenchymal tumors (PMTs) developed in the bone or soft tissue. Diagnostic delay should be addressed, and ideal techniques to localize PMTs and efficient treatment options should be explored to improve the outcomes of this rare disease. To clarify the detailed clinical course and outcomes of TIO patients, retrospective questionnaire surveys were conducted among physicians from the Japanese Society for Bone and Mineral Research (JSBMR) and the Japan Endocrine Society (JES). The primary survey collected the number of TIO patients between January 2007 and December 2018. The secondary survey aimed to obtain the detailed characteristics, laboratory data, and outcomes. Eighty-eight patients (52 males, mean: 52 years old) were included, and 24 patients were clinically diagnosed with TIO without localized PMTs. The median duration from the onset to detection of high FGF23 levels was 3.4 years, with 77 patients being initially misdiagnosed. Among the methods used to detect small, localized PMTs (≤10 mm), fluorine-18-fluorodeoxyglucose-positron emission tomography/ computed tomography and somatostatin receptor scintigraphy were less sensitive than somatostatin receptor positron emission tomography/computed tomography (SRPET/CT). Systemic venous sampling (SVS) of FGF23 was performed in 53 patients; among them, SVS was considered useful for detecting localized PMTs in 45 patients with diverse tumor sizes. Finally, 45 patients achieved biochemical remission by surgery, 39 patients continued pharmaceutical treatment, including burosumab (11 patients), and four patients died. These results encouraged us to further increase the awareness of TIO and to improve the accessibility of SRPET/CT and SVS. Further evidence about the efficacy of new pharmaceutical treatments is awaited.

show abstract

Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours

Abstract: Ga-DOTA-TOC PET/CT is an accurate imaging modality in the detection of TIO; in particular, it is worthwhile after failure of somatostatin receptor SPECT(/CT) or FDG PET/CT.

Cited by 31 publications

References 37 publications

Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis

Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis

Molecular Imaging with 68Ga Radio-Nanomaterials: Shedding Light on Nanoparticles

Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective Surveillance

Contact Info

Product

Resources

About